Plain-English translation of NCT06822010 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new way to treat high-grade cancer in the upper urinary tract (the kidney and ureter) by delivering two chemotherapy drugs—gemcitabine and Jelmyto—directly into the affected kidney through a thin tube called a nephrostomy tube. The goal is to shrink or eliminate the cancer while keeping your kidney working, rather than removing it surgically. Researchers will track how well this treatment works and whether it prevents the cancer from coming back.
Many patients with high-grade upper urinary tract cancer currently have their entire kidney removed as standard treatment, which can affect long-term health. This trial is testing whether this new medication delivery method can control the cancer effectively while letting you keep your kidney.
You likely qualify if…
You likely don't qualify if…
You will receive six weekly doses of the medication delivered directly into your kidney through a nephrostomy tube (a small tube placed in your kidney to drain urine). After six weeks, your doctors will check how well the cancer is responding. Depending on the results, you may receive six more weeks of treatment or switch to a standard maintenance regimen. Throughout the approximately 3-year study, you will have regular follow-up visits to monitor your cancer, kidney function, and overall health.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
United States